SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.

CONCLUSION: Efficacy in mild to severe AR of 6 SQ-HDM compared with placebo was demonstrated by statistically significant improvements in TCRS and Rhinitis Quality of Life Questionnaire score in subjects with AR present at baseline. The treatment was well tolerated.
TRIAL REGISTRATION: EudraCT, no 2006-001795-20; ClinicalTrials.gov, identifier NCT00389363.
PMID: 25624131 [PubMed - in process]

Source: Annals of Allergy, Asthma and Immunology - February 1, 2015 Category: Allergy & Immunology Authors: Mosbech H, Canonica GW, Backer V, de Blay F, Klimek L, Broge L, Ljørring C Tags: Ann Allergy Asthma Immunol Source Type: research